BioRock Ventures

BioRock Ventures is a venture capital firm based in Palo Alto, California, founded in 2019. The firm specializes in investing in life sciences and biopharmaceutical startups that focus on developing innovative treatments for serious medical diseases. By targeting early-stage companies, BioRock Ventures aims to support the advancement of cutting-edge therapies that address critical health challenges.

Mary Wheeler

Founder, Managing Director

3 past transactions

Celldom

Venture Round in 2021
Celldom, Inc. is a research tools company specializing in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing the diversity within cell populations. Founded in 2016 and based in Durham, North Carolina, the company has developed the TrapTx Analyzer System, which uniquely integrates phenotypic and genomic data at a large scale, capable of analyzing tens of thousands of cells in a single experiment. This technology facilitates the identification and characterization of rare cells that are vital to understanding biological pathways and diseases. Celldom's initial applications focus on oncology, immunology, and stem cell biology, providing researchers with advanced tools to explore cellular heterogeneity and improve scientific outcomes.

Primmune Therapeutics

Series A in 2020
Primmune Therapeutics, Inc., a biotechnology company, develops small molecule orally administered toll-like receptor 7 (TLR7) agonist to stimulate innate immunity in cancer immunotherapy. It offers TLR7 agonist for systemic activation of innate immunity. The company’s TLR7 is an agonist for acute and chronic viral infection. The company was founded in 2017 and is based in San Diego, California.

Primmune Therapeutics

Seed Round in 2020
Primmune Therapeutics, Inc., a biotechnology company, develops small molecule orally administered toll-like receptor 7 (TLR7) agonist to stimulate innate immunity in cancer immunotherapy. It offers TLR7 agonist for systemic activation of innate immunity. The company’s TLR7 is an agonist for acute and chronic viral infection. The company was founded in 2017 and is based in San Diego, California.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.